Anondita Medicare: the next compounder after Cupid

Stock Analysis & Valuation
1

Hi everyone,

I’ve been following Anondita Medicare for a while now and thought it’d be good to open a thread here to discuss the stock. Sharing what I’ve gathered so far:

Key Highlight:

Aggressive capex: The company is going from 806M → ~1,900M+ male condom capacity in roughly 12–18 months, plus a 240M female condom plant on top. Total capex commitment is ~₹130 Cr (₹75 Cr male + ₹54.6 Cr female).

Tgt- 1000cr revenue in next 2 years.

What they do:
They manufacture flavored male condoms under the brand COBRA, and have recently started producing female condoms too. The manufacturing plant is in Noida (Sector 80), with an installed capacity of around 869 million condoms/year. They sell through retail (own brand COBRA), government tenders (AIDS Control Societies, CMSS etc.), and also do private-label manufacturing for pharma companies. They export to Southeast Asia, Africa, and the Middle East.

They used to manufacture for other brands but now focusing on selling their own COBRA brand.

Background:
The business itself dates back to 1999 when promoter Anupam Ghosh started as a proprietorship. It was only in March 2024 that it got converted to a public limited company (Anondita Medicare Ltd). The company came to the market via a ₹69 Cr SME IPO in August 2025. Promoter holding is around 62.4% post-IPO.

FY26 Numbers (year ended March 2026):

  • Revenue: ~₹137 Cr (up ~78% YoY)

  • PAT: ~₹34.3 Cr (up ~108% YoY)

  • EBITDA margin: ~38% in H2 (expanded from ~35% in H1)

  • EPS: ₹21.30

  • Debt/Equity: ~0.29

Management Commentary

  • Management is deliberately capping government business at 40–45% of revenue. Ghosh said: “We are not interested in taking more orders there. Our focus is totally on our brand and the export business.” This is a deliberate shift from the ~60% government mix in FY25.
  • On female condoms specifically, management’s numbers are aggressive: they claim 25% utilisation of 240 million female condom capacity could translate to ~₹330 Cr revenue and ~₹150 Cr profit in FY27. No binding orders or contracts back this up yet.
  • Management targets ₹1,000 Cr revenue within two years (by ~FY28), driven by exports and female condoms.

Growth Opportunities:

  • Export pivot is the biggest near-term catalyst. First export PO of ₹43.14 Cr from South Africa (via Supra Healthcare, Johannesburg) was secured in June 2026. The South African government tender requires ~1 billion pieces annually over 5 years — even a small share is material for a company doing ₹137 Cr revenue.

  • UN/UNFPA qualification is in advanced stages (hearing was in Geneva in June 2026). If cleared, this opens up global health program supply (UNFPA, USAID, etc.) — a massive volume opportunity.

  • Brazil registration for both female latex and non-latex condoms is done. They claim to be the world’s first company registered in Brazil for this.

  • Female condoms are positioned as a premium, high-margin category (30–40% higher margin than male condoms per management). Global supply is limited, and demand is supported by government/donor programs.

  • Domestic brand push: COBRA brand is growing in retail, and they’ve relaunched the COBRA Shubh Samachar pregnancy test kit through their subsidiary.

  • In-house machine fabrication: Management claims they build their own manufacturing machines and hold patents on them, which reduces capex intensity and installation time vs. peers. This is a structural cost advantage if true.

  • Company’s own FY27 target: 60–70% revenue growth, ~30% EBITDA margin, 25% export contribution.

Things to Watch:

  • Concentration risk is real. Top few clients (CMSS, NACO, state AIDS control societies) make up a large chunk. Government receivables take 120+ days to realise.

  • Competitive landscape: Cupid (Safex) is the dominant player in Indian condoms. Anondita is gaining share in government tenders and differentiating on flavored/branded retail, but Cupid has far deeper distribution.

  • Single-product risk: Despite the “healthcare” name, this is essentially a condom company. Diversification into gloves, pregnancy kits, and medicines is nascent (only ~₹19 Cr from gloves).

  • SME stock liquidity: Listed on NSE SME platform, which means lower liquidity, wider bid-ask spreads, and limited institutional coverage.

Let me know if I have missed any point and any other point which need my attention for analysing this company in detail.

Disc: Not invested but tracking

1 Like